IMab (IMAB)
(Real Time Quote from BATS)
$1.81 USD
+0.01 (0.56%)
Updated Apr 29, 2024 02:40 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
IMAB 1.81 +0.01(0.56%)
Will IMAB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IMAB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMAB
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
IMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMAB
I-Mab Announces CMO Transition, Interim Successor Named
I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
I-Mab Announces Closing of the Divestiture of Business Operations in China
I-Mab Finalizes Divestiture and Resolves Obligations